Bausch + Lomb Corporation (NYSE:BLCO) Given Average Rating of "Hold" by Brokerages

Key Points

• Bausch + Lomb Corporation has a consensus rating of "Hold" from analysts, with one sell, seven hold, and three buy recommendations.
• The average 12-month price objective for Bausch + Lomb's stock is $15.56, reflecting analysts' expectations for future performance.
• CEO Brent L. Saunders increased his stake in the company by purchasing 22,000 shares at an average price of $11.28, demonstrating insider confidence in the business.

Bausch + Lomb Corporation (NYSE:BLCO - Get Free Report) has been assigned an average rating of "Hold" from the eleven brokerages that are currently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, seven have given a hold rating and three have assigned a buy rating to the company. The average 1-year price target among brokers that have covered the stock in the last year is $15.5556.

BLCO has been the topic of several recent analyst reports. Citigroup boosted their price target on Bausch + Lomb from $13.00 to $15.00 and gave the stock a "neutral" rating in a research note on Wednesday, July 9th. Needham & Company LLC restated a "hold" rating on shares of Bausch + Lomb in a research note on Thursday, April 24th. Evercore ISI upped their price objective on Bausch + Lomb from $15.50 to $16.00 and gave the company an "outperform" rating in a research note on Tuesday, July 8th. Wells Fargo & Company upped their price objective on Bausch + Lomb from $12.00 to $15.00 and gave the company an "equal weight" rating in a research note on Thursday, July 31st. Finally, Barclays cut their price objective on Bausch + Lomb from $19.00 to $16.00 and set an "equal weight" rating on the stock in a research note on Monday, June 9th.

Bausch + Lomb Stock Up 2.9%

Shares of NYSE:BLCO traded up $0.4250 during trading on Monday, hitting $14.9250. The company's stock had a trading volume of 935,840 shares, compared to its average volume of 984,318. The company has a debt-to-equity ratio of 0.76, a quick ratio of 0.98 and a current ratio of 1.55. Bausch + Lomb has a fifty-two week low of $10.45 and a fifty-two week high of $21.69. The stock's 50-day moving average price is $13.61 and its two-hundred day moving average price is $13.59. The company has a market capitalization of $5.28 billion, a PE ratio of -19.13, a PEG ratio of 1.48 and a beta of 0.62.

Bausch + Lomb (NYSE:BLCO - Get Free Report) last released its quarterly earnings results on Wednesday, July 30th. The company reported $0.07 EPS for the quarter, topping the consensus estimate of $0.06 by $0.01. Bausch + Lomb had a positive return on equity of 2.33% and a negative net margin of 5.58%.The business had revenue of $1.28 billion for the quarter, compared to analysts' expectations of $1.25 billion. During the same quarter in the previous year, the firm posted $0.13 earnings per share. The company's revenue was up 5.1% compared to the same quarter last year. Bausch + Lomb has set its FY 2025 guidance at EPS. As a group, sell-side analysts expect that Bausch + Lomb will post 0.74 EPS for the current year.

Institutional Trading of Bausch + Lomb

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Engineers Gate Manager LP raised its position in shares of Bausch + Lomb by 210.3% during the 2nd quarter. Engineers Gate Manager LP now owns 31,970 shares of the company's stock worth $416,000 after purchasing an additional 21,668 shares during the period. BNP Paribas Financial Markets acquired a new stake in shares of Bausch + Lomb during the 2nd quarter worth approximately $592,000. PDT Partners LLC raised its position in shares of Bausch + Lomb by 182.3% during the 2nd quarter. PDT Partners LLC now owns 172,209 shares of the company's stock worth $2,240,000 after purchasing an additional 111,206 shares during the period. Glenview Capital Management LLC raised its position in shares of Bausch + Lomb by 210.8% during the 2nd quarter. Glenview Capital Management LLC now owns 1,553,855 shares of the company's stock worth $20,216,000 after purchasing an additional 1,053,855 shares during the period. Finally, Nebula Research & Development LLC raised its position in shares of Bausch + Lomb by 54.9% during the 2nd quarter. Nebula Research & Development LLC now owns 64,572 shares of the company's stock worth $840,000 after purchasing an additional 22,876 shares during the period. 11.07% of the stock is currently owned by institutional investors and hedge funds.

Bausch + Lomb Company Profile

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.